Literature DB >> 16633338

VEGF receptor signalling - in control of vascular function.

Anna-Karin Olsson1, Anna Dimberg, Johan Kreuger, Lena Claesson-Welsh.   

Abstract

Vascular endothelial growth-factor receptors (VEGFRs) regulate the cardiovascular system. VEGFR1 is required for the recruitment of haematopoietic precursors and migration of monocytes and macrophages, whereas VEGFR2 and VEGFR3 are essential for the functions of vascular endothelial and lymphendothelial cells, respectively. Recent insights have shed light onto VEGFR signal transduction and the interplay between different VEGFRs and VEGF co-receptors in development, adult physiology and disease.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16633338     DOI： 10.1038/nrm1911

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN： 1471-0072            Impact factor:   94.444


  1099 in total

1.  VEGF and VEGFR1 levels in different regions of the normal and preeclampsia placentae.

Authors:  Akriti S Sahay; Anjali T Jadhav; Deepali P Sundrani; Girija N Wagh; Savita S Mehendale; Preeti Chavan-Gautam; Sadhana R Joshi
Journal:  Mol Cell Biochem       Date:  2017-08-02       Impact factor: 3.396

2.  Endogenous vascular endothelial growth factor-A (VEGF-A) maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription.

Authors:  Guangqi E; Ying Cao; Santanu Bhattacharya; Shamit Dutta; Enfeng Wang; Debabrata Mukhopadhyay
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

3.  Protein tyrosine phosphatase 1B impairs diabetic wound healing through vascular endothelial growth factor receptor 2 dephosphorylation.

Authors:  Jing Zhang; Limin Li; Jing Li; Yuan Liu; Chen-Yu Zhang; Yujing Zhang; Ke Zen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

4.  A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.

Authors:  J Kankanala; A M Latham; A P Johnson; S Homer-Vanniasinkam; C W G Fishwick; S Ponnambalam
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

5.  VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.

Authors:  Jiasheng Zhang; Teresa Silva; Timur Yarovinsky; Thomas D Manes; Sina Tavakoli; Lei Nie; George Tellides; Jordan S Pober; Jeffrey R Bender; Mehran M Sadeghi
Journal:  Circ Res       Date:  2010-06-10       Impact factor: 17.367

6.  Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.

Authors:  Jeremy M Sivak; Allison C Ostriker; Amber Woolfenden; John Demirs; Rosemarie Cepeda; Debby Long; Karen Anderson; Bruce Jaffee
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

7.  Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles.

Authors:  Xin Ma; Zhaohui Li; Ting Li; Linwensi Zhu; Zhenshengnan Li; Nan Tian
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

8.  ERK3 promotes endothelial cell functions by upregulating SRC-3/SP1-mediated VEGFR2 expression.

Authors:  Wei Wang; Ka Bian; Sreeram Vallabhaneni; Bin Zhang; Ray-Chang Wu; Bert W O'Malley; Weiwen Long
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

9.  NFATc1 regulates lymphatic endothelial development.

Authors:  Rishikesh M Kulkarni; James M Greenberg; Ann L Akeson
Journal:  Mech Dev       Date:  2009-02-20       Impact factor: 1.882

10.  Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding.

Authors:  Gerdy B ten Dam; Els M A van de Westerlo; Anurag Purushothaman; Radu V Stan; Johan Bulten; Fred C G J Sweep; Leon F Massuger; Kazuyuki Sugahara; Toin H van Kuppevelt
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.